Get the CPRX Research Report and
Also Receive Our Top Trades for 2016!

Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare neuromuscular and neurological diseases, today reported financial results for the fourth quarter and the year-ended December 31, 2016. Began enrolling patients into second Phase 3 clinical trial to evaluate the efficacy and safety of Firdapse in patients with Lambert-Eaton Myasthenic Syndrome (LEMS). (See Research Report)
Download Research Report
on CPRX Now